スタッフ紹介

教授 豊嶋 崇徳

写真:教授 豊嶋 崇徳
略歴
  • 1980年 鳥取県立米子東高等学校卒業
  • 1986年 九州大学医学部卒業
  • 1992年 唐津赤十字病院 内科
  • 1993年 北九州市立医療センター 内科
  • 1996年 岡山大学第二内科助手
  • 1997年 米国Harvard大学Dana-Farber Cancer Institute研究員
  • 1999年 米国Michigan大学がんセンター研究員
  • 2000年 米国Michigan大学内科ファカルティー
  • 2002年 岡山大学病院 血液・腫瘍・呼吸器・アレルギー内科助手
  • 2004年 九州大学病院 遺伝子・細胞療法部 准教授
  • 2010年 文部科学省 研究振興局 学術調査官併任
  • 2012年 北海道大学大学院 医学研究科 内科学講座 血液内科学 教授
  • 2014年 国際医療部長
  • 2016年 病院長補佐
  • 2016年 HIV診療支援センター長
  • 2017年 造血幹細胞移植連携支援センター部長
  • 2018年 北海道大学病院 検査・輸血部 部長
  • 2020年 北海道大学病院 超音波センター長
賞罰
  • 1999年 米国造血細胞移植学会 最高論文賞
  • 2016年 平成27年度北海道大学大学院医学研究科・医学部医学科 優秀研究賞
  • 2019年 一般社団法人日本造血細胞移植学会 第1回日本造血細胞移植学会学会賞
  • 2020年 2020年度 第3回伊藤太郎特別賞
  • 2021年 令和2年度 北海道大学教育研究総長表彰
所属学会
  • 日本内科学会(評議員、認定医,総合内科専門医,指導医)
  • 日本血液学会(理事,代議員,専門医,指導医)
  • 日本造血・免疫細胞療法学会(理事長,理事,評議員)
  • 日本輸血・細胞治療学会(理事,評議員,認定医)
  • 日本臨床腫瘍学会
  • 日本エイズ学会
  • 日本リンパ網内系学会
  • 日本組織適合性学会
  • 米国血液学会(Scientific Committee)
  • 米国造血細胞移植学会
  • APBMT: Asian-Pacific Blood and Marrow Transplantation Group (Scientific Committee)
  • アジア細胞治療学会(理事)
専門領域
  • 血液学,造血細胞移植学,輸血学,免疫学
代表的業績
  1. Teshima T, et al. CNS involvement in ATL. Cancer 1990; 65: 327.
  2. Teshima T, et al. Cytotoxic drugs and cytotoxic drugs/G-CSF mobilization of PBSCs and their use for autografting. Bone Marrow Transplant 1992;10: 215.
  3. Nagafuji K, et al. Hematopoietic progenitor cells from patient with ATL are not infected with HTLV-I. Blood 1993; 82: 2823.
  4. Teshima T, et al. BMT for EBV-associated NK cell-large granular lymphocyte leukemia. Lancet 1996; 372: 1124.
  5. Hill GR, et al. IL-11 promotes T cell polarization and prevents acute GVHD after allogeneic BMT. J Clin Invest 1998; 102: 115.
  6. Teshima T, et al. IL-11 separates GVL effects from GVHD after BMT. J Clin Invest 1999; 104: 317.
  7. Hill GR, et al. Differential roles of IL-1 and TNF-α on GVHD and GVL. J Clin Invest 1999; 104: 459.
  8. Pan L, et al. G-CSF-mobilized allogeneic SCT maintains GVL effects through a perforin dependent pathway while preventing GVHD. Blood 1999; 93: 4071.
  9. Krijanovski O, et al. Keratinocyte growth factor separates GVL effects from GVHD. Blood 1999; 94: 825.
  10. Reddy P, et al. IL-18 regulates acute GVHD by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433.
  11. Cooke K, et al. LPS antagonism reduces GVHD and preserves GVL activity after BMT. J Clin Invest 2001; 107: 1581.
  12. Teshima T, et al. Tumor cell vaccine elicits potent anti-tumor immunity after allogeneic T-cell depleted BMT. Cancer Res 2001; 61: 162.
  13. Teshima T, et al. Acute GVHD does not require alloantigen expression on host epithelium. Nature Med 2002; 8: 575.
  14. Ordemann R, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute GVHD. J Clin Invest 2002; 109: 1249.
  15. Teshima T, et al. Flt3 ligand therapy for recipients of allogeneic BMT expands host CD8α+ dendritic cells and reduces acute GVHD. Blood 2002; 99: 1825.
  16. Teshima T, et al. DLI from immunized donors increases tumor vaccine efficacy after allogeneic BMT. Cancer Res 2002; 62: 796.
  17. Reddy P, et al. IL-18 preserves perforin dependent GVL effect after allogeneic BMT. Blood 2002; 100: 3429.
  18. Teshima T, et al. Impaired thymic negative selection causes autoimmune GVHD. Blood 2003; 102: 429.
  19. Reddy P, et al. Pretreatment of donors with IL-18 attenuates acute GVHD via STAT6 and preserves GVL effects. Blood 2003; 101: 2877.
  20. Ichiba T, et al. Early changes in gene expression profiles of hepatic GVHD uncovered by ologonucleotide microarrays. Blood 2003; 102: 763.
  21. Maeda Y, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute GVHD. Blood 2005; 105: 2023.
  22. Matsuoka K, et al. Fetal tolerance to maternal antigens improves the outcome of allogeneic BMT by a CD4+CD25+ T cell-dependent mechanism. Blood 2006; 107: 404.
  23. Sakoda Y, et al. Donor-derived thymic-dependent T cells cause chronic GVHD. Blood 2007; 109: 1756.
  24. Koyama M, et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate GVHD as antigen-presenting cells. Blood 2009; 113: 2088.
  25. Aoyama K, et al. Improved outcome of allogeneic BMT due to breast-feeding-induced tolerance to maternal antigens. Blood 2009; 113: 1829.
  26. Asakura S, et al. Alloantigen expression on non-hematopoietic cells reduces GVL effects. J Clin Invest 2010; 120: 2370.
  27. Kikushige Y, et al. TIM-3 is a promising target to selectively kill AML stem cells. Cell Stem Cell 2010; 7: 708.
  28. Teshima T: Th1 and Th17 join forces for acute GVHD. Blood 2011; 118: 4765
  29. Takashima S, et al. The Wnt agonist R-spondin1 regulates systemic GVHD by protecting intestinal stem cells. J Exp Med 2011; 208: 285.
  30. Hashimoto D, et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic HSCT. J Exp Med 2011; 208: 1069.
  31. Ferrara JL, et al. Regenerating islet-derived 3α is a biomarker of gastrointestinal GVHD. Blood 2011; 118: 6702.
  32. Nishimori H, et al. Synthetic retinoid Am80 ameliorates chronic GVHD by downregulating Th1 and Th17. Blood 2012; 119: 285.
  33. Harris AC, et al. Plasma biomarker of loser gastrointestinal and liver acute GVHD. Blood 2012; 119: 2960.
  34. Eriguchi Y, et al. GVHD disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood 2012; 120: 223.
  35. Kuriyama T, et al. Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. Blood 2012; 120: 4058.
  36. 39. Shima T, et al. Quantification of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic stem cell transplantation. Blood 2013; 121: 840.
  37. Aoyama K, et al. Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood 2013; 122: 2125.
  38. Teshima T. JAK inhibitors: a home run for GVHD patients? Blood 2014; 123: 3691.
  39. Teshima T. The primacy of IL-6 in IPS? Blood 2015; 125: 2320.
  40. Uryu H, et al. α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. Blood 2015; 125: 3014.
  41. Sugita J, et al: Japan Study Group for Cell Therapy and Transplantation. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. Biol Blood Marrow Transplant 2015; 21: 1646.
  42. Teshima T, et al. Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant 2016; 22: 11.
  43. Shimoji S, et al. Graft-versus-host disease targets ovary and causes female infertility in mice. Blood 2017; 129: 1216.
  44. Hayase E, et al. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease. J Exp Med 2017; 214: 3507.
  45. Yamakawa T, et al. Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. Blood 2018; 131: 1476.
  46. Takahashi S, et al. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. Blood 2018. [Epub ahead of print]
  47. Mathew NR, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 2018; 24: 282.
  48. Schuster SJ, et al; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45.
  49. Noviello M, et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun 2019; 10: 1065.
  50. Toffalori C, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 2019; 25: 603.
  51. Stein-Thoeringer CK, et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science 2019; 366: 1143.
  52. Peled JU, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med 2020; 382: 822.
  53. Ara T, et al. Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8. Sci Transl Med 2020; 12: eaaw0720.
  54. Yokota I, et al. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis 2020: ciaa1388.
  55. Yokota I, et al. A novel strategy for SARS-CoV-2 mass-screening using quantitative antigen testing of saliva: a diagnostic accuracy study. Lancet Microbes 2021.
コメント

情熱にあふれる若者と将来を語りあうのが何より楽しみです。